ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.

The only FDA-cleared AI system delivering MRI-equivalent cardiac measurements from standard ultrasound. While the near-direct comparable trades around $2.94 billion, Ventripoint Diagnostics (TSXV: VPT / *OTC: VPTDF) commands the only scalable solution for the heart’s most difficult chamber.***

The information gap between retail and institutions is closing faster than most realize.

The Problem and the Solution

The Right Ventricle is the most anatomically complex chamber of the human heart. Its irregular crescent shape makes accurate measurement nearly impossible using conventional ultrasound. For decades, cardiologists have relied on expensive, time-consuming cardiac MRI as the only reliable method.

Ventripoint Diagnostics (TSXV: VPT / OTC: VPTDF) solved this. Its VMS+ technology uses AI-powered Knowledge Based Reconstruction to generate 3D cardiac measurements from standard 2D ultrasound images. The system delivers MRI-level accuracy in minutes, at a fraction of the cost, using equipment that already exists in every hospital.

Over 60 peer-reviewed publications validate the clinical accuracy[1]. Mayo Clinic, Duke University Hospital, and DHZC in Germany (ranked by Newsweek as among the world’s top cardiac hospitals[2]) have all acquired the system for clinical use.

The Valuation Absurdity: HeartFlow vs. Ventripoint

HeartFlow (NASDAQ: HTFL) uses AI to model coronary arteries from CT scans. It is a validated business model with significant market traction.

The math is simple. HeartFlow commands a market capitalization of approximately $2.94 billion[3].

If Ventripoint were valued at even one-quarter of that comparable, it would imply a market cap of approximately $735 million USD.

Currently, Ventripoint Diagnostics (TSXV: VPT / OTC: VPTDF) trades at a fraction of that valuation. This is not a speculative bet on unproven science; this is an arbitrage opportunity on a proven business model that the broader market has not yet priced in.

https://youtu.be/CQnfzuMrBHs?si=X8gTJDuItCOz8aZ8

Market Leadership: Uncontested Clinical Utility

VMS+ serves three massive markets:

Pacemaker Patients: 3 million pacemaker patients in the US cannot undergo MRI scans[4]. Ventripoint’s magnet-free sensor technology (VMS+ 4.0, under FDA review) will allow these patients to receive MRI-equivalent diagnostics using standard ultrasound. No MRI suite. No anesthesia. Just accurate, accessible cardiac imaging for patients who have been medically excluded for decades.

Heart Valve Market: The global +US$8.5 billion heart valve repair and replacement market is growing at 10% annually towards a projected US$22.25 billion market by 2034[5]. Ventripoint is positioning VMS+ as the diagnostic standard for surgical planning and post-operative monitoring.

China Market Entry: Through its partnership with Lishman Global, Ventripoint is entering a market of +32,000 hospitals[6]. China has twice the rate of cardiovascular hospital admissions compared to North America. Lishman Global has already placed its first purchase order and signed a non-binding term sheet for an exclusive license in China.

Hospital Validation: The Credibility Lock

Ventripoint is deployed at:

Mayo Clinic
Duke University Hospital
DHZC Germany
SickKids – The Hospital for Sick Children
Phoenix Children’s Hospital
Seattle Children’s Hospital

Endorsed by the Ollie Hinkle Heart Foundation for nationwide deployment through its Take Heart program (13 U.S. hospital partners, 30 more expected).

“Ventripoint is the only AI technology like this in this category. There’s nobody else doing this.”

– Beth Rumack, Chief Operating Officer of the Ollie Hinkle Heart Foundation.

The M&A Signal

In June 2025, Ventripoint engaged Fournel Advisory to provide M&A and strategic advisory services[7]. Fournel Advisory has completed over 50 transactions in healthcare and life sciences since 2013[8].

When a small-cap medical device company engages an M&A advisory firm with 50+ healthcare transactions, the signal is unambiguous. Management is preparing the company for sale or strategic partnership.

Ventripoint has also transitioned to a Device-as-a-Service (DaaS) subscription model[9]. Acquirers pay premiums for recurring revenue. One-time hardware sales are valued at 1-3x revenue multiples. Subscription software is valued at 5-15x revenue multiples[10].

Management is not building a lifestyle company. Management is building an asset designed for acquisition.

The Timeline That Changes Everything

May 2024: Duke University Health Center purchases VMS+ technology.[11]
August 2024: Health Canada Medical Device License received for VMS+ 4.0.[12]
October 2024: EU CE Mark received, opening the European market.[13]
January 2025: FDA submission updated to address final cybersecurity and AI requirements.[14]
February 2025: FDA 510(k) Clearance received for VMS+ 4.0, officially unlocking the pacemaker market.[15]
June 2025: Fournel Advisory engaged to lead financial advisory and M&A strategy.[16]
July 2025: Lishman Global places first purchase order for China market entry.[17]
October 2025: Collaboration announced with Providence Health Care Ventures to validate VMS+ at St. Paul’s Hospital.[18]

Every milestone is a potentially strong repricing opportunity… and there are more to come!

https://youtu.be/aHG83yzw3nE?si=1z-0_YLo8EANrtQ4

The Bottom Line

Ventripoint Diagnostics (TSXV: VPT / OTC: VPTDF) has FDA clearance for its VMS+ AI solution with MRI-equivalent accuracy, with next-generation capabilities under regulatory review.

The world’s leading cardiac institutions have validated the technology and acquired the systems.

Management has engaged M&A advisors and pivoted to a recurring revenue model designed to maximize exit valuation.

The cardiac AI comparable has recently traded around $2.94 billion.

Ventripoint trades at a fraction of that valuation.

The market always discovers value. The only question is who will be holding when it does.

TSXV: VPT / OTC: VPTDF

For more information, visit ventripoint.com or contact the company directly at info@ventripoint.com.

Disclaimer:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (“BAY”) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

[1] https://ventripoint.com/products/publications-clinical-research/

[2] https://www.charite.de/en/service/press_reports/artikel/detail/newsweek_ranking_charite_once_again_named_among_the_worlds_top_10_hospitals/

[3] HeartFlow (NASDAQ: HTFL) market capitalization of ~$2.94B is based on approx. 85.1M shares outstanding and a 50-day moving average share price of ~$34.50 as of November 2025. Valuation gaps are theoretical and imply potential based on comparative analysis, not guaranteed future performance. Source: NASDAQ / Public Filings.

[4] https://www.yalemedicine.org/conditions/cardiac-pacemaker

[5] https://www.factmr.com/report/heart-valve-repair-and-replacement-market

[6] https://ventripoint.com/wp-content/uploads/2025/07/2025-07-11-License-Termsheet-Signed-with-Lishman.final_.pdf

[7] https://ventripoint.com/wp-content/uploads/2025/06/2025-06-17-Fournel-Advisory.final_.pdf

[8] https://fournel-advisory.com/en/transactions/

[9] https://ventripoint.com/wp-content/uploads/2025/01/2025-01-23-Shareholder-Update.pdf

[10] https://www.saas-capital.com/blog-posts/private-saas-company-valuations-multiples/

[11] https://ventripoint.com/wp-content/uploads/2024/05/2024-05-01-Duke-Health-NR.final_.pdf

[12] https://ventripoint.com/wp-content/uploads/2024/08/2024-08-21-Ventripoint-Receives-Health-Canada-License-for-VMS-4.pdf

[13] https://ventripoint.com/wp-content/uploads/2024/10/2024-10-24-Ventripoint.pdf

[14] https://ventripoint.com/wp-content/uploads/2025/01/2025-01-21-Submission-of-VMS4-to-FDA.pdf

[15] https://ventripoint.com/wp-content/uploads/2025/02/2025-02-27-VMS4-Clearance-by-FDA.pdf